Douglas Levine

Douglas Levine played a central role in the TCGA comprehensive molecular characterization of endometrial carcinoma, which identified four molecular subtypes (POLE ultramutated, MSI-high, copy-number-low, copy-number-high) with distinct biology and prognostic significance. His subsequent analyses have extended molecular classification to endometrial carcinosarcoma, identifying POLE mutations as conferring ultramutated status and immunotherapy sensitivity in this rare tumor. He has contributed to the ProMisE clinical molecular classification scheme now adopted in international guidelines.